Evidence map›Paper›PMID 29066452›Full record

Trial reportJournal of the American Heart Association2017

Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.

Claes Held, Harvey D White, Ralph A H Stewart, Andrzej Budaj, Christopher P Cannon, Judith S Hochman, Wolfgang Koenig, Agneta Siegbahn, Philippe Gabriel Steg, Joseph Soffer and 4 more

2 registry-linked trialsOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of the American Heart Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 150 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 6 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05911724 completedstarted 2023, after this paper: background citation

Diagnostic and Prognostic Roles of Inflammatory Biomarkers in Coronary Heart Disease and Heart Failure Patients Treated With Empagliflozin.

Ran2023Enrolled180Registered outcomes7Posted comparisons0ConditionsHeart Failure, Stable AnginaArmsCAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study, Group I Healthy, HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
PMID 30942129PMID 24766981PMID 23847549PMID 18160340other papers from this trial
Open the trial in the graph
NCT00799903 phase3completednot on this map

LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

TypeinterventionalSponsorGlaxoSmithKlineRan2008 to 2013Enrolled15,828ConditionsAtherosclerosisArmsDarapladib, Placebo
3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 6 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Beyond the beats: a systematic review of the underlying inflammatory pathways between atrial fibrillation and cognitive decline.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Impact of Cardiovascular Diseases on COVID-19: A Systematic Review.Medical science monitor : international medical journal of experimental and clinical research · 2021
    Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 7 countries.

Claes HeldDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden claes.held@ucr.uu.se.
Harvey D WhiteGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
Ralph A H StewartGreen Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
Andrzej BudajPostgraduate Medical School, Grochowski Hospital, Warsaw, Poland.
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Boston, MA.
Judith S HochmanDepartment of Medicine, NYU Langone Medical Center, New York, NY.
Wolfgang KoenigDepartment of Internal Medicine II-Cardiology, University of Ulm Medical Center, Ulm, Germany.
Agneta SiegbahnUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Philippe Gabriel StegDépartement Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France.
Joseph SofferMetabolic Pathways and Cardiovascular Therapeutic Area, GlaxoSmithKline, Collegeville, PA.
W Douglas WeaverHenry Ford Heart and Vascular Institute, Detroit, MI.
Ollie ÖstlundUppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
Lars WallentinDepartment of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden.
STABILITY Investigators
Uppsala University · SEAuckland City Hospital · NZBrigham and Women's Hospital · USFrench Clinical Research Infrastructure Network · FRGrochowski Hospital · PLHenry Ford Hospital · USNYU Langone Health · USPathways Behavioral Services · USTechnical University of Munich · DE

Funding

Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5M
NCATS NIH HHS UL1 TR001445
6 · The paper itself

Abstract

backgroundEvaluation of cardiovascular prognosis in patients with stable coronary heart disease is based on clinical characteristics and biomarkers indicating dysglycemia, dyslipidemia, renal dysfunction, and possibly cardiac dysfunction. Inflammation plays a key role in atherosclerosis, but the association between inflammatory biomarkers and clinical outcomes is less studied in this population. METHODS AND

resultsOverall, 15 828 patients with coronary heart disease in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial were randomized to treatment with darapladib or placebo and observed for a median of 3.7 years. In 14 611 patients, levels of interleukin-6 (IL-6) and high-sensitivity C-reactive protein were measured in plasma samples: median levels were 2.1 (interquartile range, 1.4-3.2) ng/L and 1.3 (interquartile range, 0.6-3.1) mg/L, respectively. Associations between continuous levels or quartile groups and adjudicated outcomes were evaluated by spline graphs and Cox regression adjusted for clinical factors and cardiovascular biomarkers. IL-6 was associated with increased risk of major adverse cardiovascular events (quartile 4 versus quartile 1 hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.30-1.97;

conclusionsIL-6, an upstream inflammatory marker, was independently associated with the risk of major adverse cardiovascular events, cardiovascular and all-cause mortality, myocardial infarction, heart failure, and cancer mortality in patients with stable coronary heart disease. IL-6 might reflect a pathophysiological process involved in the development of these events. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00799903.

Indexed as

AgedBenzaldehydesBiphenyl CompoundsCause of DeathCoronary DiseaseC-Reactive ProteinDiethylaminesFemaleHumansInflammation MediatorsInterleukin-6Kaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasmsBenzaldehydesBiphenyl CompoundsC-Reactive ProteindarapladibDiethylaminesIL6 protein, humanInflammation MediatorsInterleukin-6OximesPhospholipase A2 InhibitorsPyrimidinonesSulfidescoronary diseaseC‐reactive proteininflammationinterleukin‐6white blood cells

Identifiers

PMID29066452
PMCPMC5721818
OpenAlexW2765664486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.